-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CwlHxmhJAC+zCIgheLp1nbXK/xdS2AjemUChb4WLvkhJ2CT7g7zglNoNV7S+VLnQ z/2ybSyBHKYMxpIupVVC7A== 0001367644-08-000068.txt : 20080821 0001367644-08-000068.hdr.sgml : 20080821 20080821140950 ACCESSION NUMBER: 0001367644-08-000068 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080815 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20080821 DATE AS OF CHANGE: 20080821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 081031962 BUSINESS ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (301) 795-1800 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 form8-k_082108.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 15, 2008

Emergent BioSolutions Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33137

14-1902018

(State or Other Jurisdiction

of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

 

2273 Research Boulevard, Suite 400, Rockville, Maryland

20850

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On August 15, 2008, Emergent BioDefense Operations Lansing Inc. (“Emergent BioDefense Operations”), a wholly owned subsidiary of Emergent BioSolutions Inc., entered into an amendment (the “Amendment”) to that Loan Agreement with Fifth Third Bank that was entered into on June 11, 2007 (the “Loan Agreement”).

 

The Amendment provides that the maturity date on the revolving line of credit under the Loan Agreement shall be June 1, 2009, or as otherwise extended beyond such date by Fifth Third Bank. The Amendment also permits the issuance of letters of credit in addition to cash advances under the line of credit. Finally, the Amendment provides that interest accrues at an annual rate equal to the one-month LIBOR index rate plus 2.0%.

 

Except as set forth above, no other terms of the Loan Agreement were amended, and the Loan Agreement remains in full force and effect.

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 21, 2008

EMERGENT BIOSOLUTIONS INC.

 

By:

/s/ R. Don Elsey_____________

R. Don Elsey

Senior Vice President Finance, Chief

Financial Officer and Treasurer

 

 

 

 

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----